论文部分内容阅读
新型口服抗凝药正逐渐作为非瓣膜性心房颤动患者卒中预防的一线抗凝治疗选择。然而新型口服抗凝药价格昂贵,不适用于孕妇、儿童、瓣膜病及严重肾功能不全患者,大多数患者仍需使用华法林抗凝治疗。华法林被推荐用于系统性血栓、卒中、静脉血栓栓塞的防治。新型口服抗凝药时代如何优化华法林抗凝治疗尤为重要。
New oral anticoagulants are increasingly being chosen as first-line anticoagulants for stroke prevention in patients with nonvalvular atrial fibrillation. However, the new oral anticoagulants are expensive and not suitable for pregnant women, children, valvular diseases and patients with severe renal insufficiency. Most patients still require warfarin anticoagulation. Warfarin is recommended for the prevention and treatment of systemic thrombosis, stroke and venous thromboembolism. How to optimize warfarin anticoagulant therapy is particularly important in the era of new oral anticoagulants.